Friday 6 November 2026 Export TARS’s income statement to Excel — free account

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.

Revenue: +63.9%
EPS: −4,699.1%
Free cash flow: −144.1%
Total debt: +0.90%

Quarter to September 2026, against a year earlier

68.81 1.29 +1.91%

Follow TARS

Alert me

Market cap: $3.3B
P/E: 0.0×
Fwd P/E: −10.6×
Dividend yield: —
F-score: 5/9
Altman Z: 9.54
Beneish M: −1.78
Dividend safety: n/a

Overview

Tarsus Pharmaceuticals, Inc. (TARS) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Tarsus Pharmaceuticals, Inc. (TARS) trades at a P/B ratio of 30.1×. Over the past ten years it has ranged from 0.0× (December 2020) to 35.1× (September 2026); the current reading is higher than 98% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TARS/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Tarsus Pharmaceuticals, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TARS/metrics/pb-ratio">Tarsus Pharmaceuticals, Inc. (TARS) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	10.0×	7.43%
FY2024	9.3×	208.38%
FY2023	3.0×	63.39%
FY2022	1.8×	(33.65%)
FY2021	2.8×	—

Period	P/B ratio	Change
Sep 2026	35.1×	345.32%
Jun 2026	7.9×	(8.79%)
Mar 2026	8.6×	(13.32%)
Dec 2025	10.0×	31.83%
17 more quarters	Free account

Against its own ten years

Low 0.0× High 35.1×

Ten-year median 3.3×

Current reading's percentile 98

Company	P/B ratio
TLX Telix Pharmaceuticals Limited compare	n/m
CELC Celcuity, Inc. compare	n/m
ACAD ACADIA Pharmaceuticals Inc. compare	2.6×
ELVN Enliven Therapeutics, Inc. compare	3.3×
DNLI Denali Therapeutics Inc. compare	4.0×
DYN Dyne Therapeutics, Inc. compare	4.1×
VKTX Viking Therapeutics, Inc. compare	5.2×
VRDN Viridian Therapeutics, Inc. compare	5.5×
TARS Tarsus Pharmaceuticals, Inc.	30.1×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Tarsus Pharmaceuticals, Inc. (TARS) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on TARS

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on TARS

Stockrow Weekly